ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
World Health Organization, 2017. 681 Progress report on the elimination of human onchocerciasis, 2016–2017. Wkly Epidemiol Rec 92: 681–694.
-
2.
Katabarwa MN, Richards FO Jr., 2001. Community-directed health (CDH) workers enhance the performance and sustainability of CDH programmes: experience from ivermectin distribution in Uganda. Ann Trop Med Parasitol 95: 275–286.
-
3.
Katabarwa MN, Habomugisha P, Eyamba A, Byamukama E, Nwane P, Arinaitwe A, Musigire J, Tushemereirwe R, Khainza A, 2016. Community-directed interventions are practical and effective in low-resource communities: experience of ivermectin treatment for onchocerciasis control in Cameroon and Uganda, 2004–2010. Int Health 8: 116–123.
-
4.
Hotez PJ, Kamath A, 2009. Neglected tropical diseases in sub-Saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 3: e412.
-
5.
Akinbo FO, Okaka CE, 2010. Hyperendemicity of onchocerciasis in Ovia northeast local government area, Edo state, Nigeria. Malays J Med Sci 17: 20–24.
-
6.
Akinbo FO, Okaka CE, 2010. Hyperendemicity of onchocerciasis in Ovia northeast local government area, Edo state, Nigeria. East Afr J Public Health 7: 84–86.
-
7.
Wogu M, Okaka C, 2008. Prevalence and socio-economic effects of onchocerciasis in Okpuje, Owan West local government area, Edo state, Nigeria. Int J Biomed Health Sci 4: 113–118.
-
8.
Tekle AH, Zoure HG, Noma M, Boussinesq M, Coffeng LE, Stolk WA, Remme JH, 2016. Progress towards onchocerciasis elimination in the participating countries of the African programme for onchocerciasis control: epidemiological evaluation results. Infect Dis Poverty 5: 66.
-
9.
APOC, WHO, 2010. Year 2010 Progress Report. Ouagadougou, Burkina Faso: World Health Organization, 33.
-
10.
Otubanjo OA, Adeoye GO, Ibidapo CA, Akinsanya B, Okeke P, Atalabi T, Adejai ET, Braide E, 2008. Adverse reactions from community directed treatment with ivermectin (CDTI) for onchocerciasis and loiasis in Ondo state, Nigeria. Rev Biol Trop 56: 1635–1643.
-
11.
Katabarwa M, Richards F, 2014. Twice-yearly ivermectin for onchocerciasis: the time is now. Lancet Infect Dis 14: 373–374.
-
12.
Cupp EW, Cupp MS, 2005. Short report: impact of ivermectin community-level treatments on elimination of adult Onchocerca volvulus when individuals receive multiple treatments per year. Am J Trop Med Hyg 73: 1159–1161.
-
13.
Budge PJ, Sognikin E, Akosa A, Mathieu EM, Deming M, 2016. Accuracy of coverage survey recall following an integrated mass drug administration for lymphatic filariasis, schistosomiasis, and soil-transmitted helminthiasis. PLoS Negl Trop Dis 10: e0004358.
-
14.
Baker MC, Krotki K, Sankara DP, Trofimovich L, Zoerhoff KL, Courtney L, Chowdhury D, Linehan M, 2013. Measuring treatment coverage for neglected tropical disease control programs: analysis of a survey design. Am J Epidemiol 178: 268–275.
-
15.
Cromwell EA, Ngondi J, McFarland D, King JD, Emerson PM, 2012. Methods for estimating population coverage of mass distribution programmes: a review of practices in relation to trachoma control. Trans R Soc Trop Med Hyg 106: 588–595.
-
16.
Commission NP, International I, 2014. Nigeria Demographic and Health Survey 2013. Abuja, Nigeria and Rockville, MD: National Population Commission, Federal Republic of Nigeria and ICF International.
-
17.
Center NTDS, 2016. Supervisor’s Coverage Tool. Available at: http://www.ntdsupport.org/resources/supervisors-coverage-tool. Accessed December 6, 2017.
-
18.
WHO, 2016. Guidelines for Stopping Mass Drug Administration and Verifying Elimination of Human onchocerciasis: Criteria and Procedures. Geneva, Switzerland: World Health Organization.
-
19.
Plaisier AP, van Oortmarssen GJ, Habbema JD, Remme J, Alley ES, 1990. ONCHOSIM: a model and computer simulation program for the transmission and control of onchocerciasis. Comput Methods Programs Biomed 31: 43–56.
-
20.
Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, Boatin BA, Habbema JD, 2002. Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull World Health Organ 80: 384–391.
-
21.
Cupp EW, Sauerbrey M, Richards F, 2011. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan®) monotherapy. Acta Trop 120 (Suppl 1): S100–S108.
-
22.
Higazi TB et al. 2013. Interruption of Onchocerca volvulus transmission in the Abu Hamed focus, Sudan. Am J Trop Med Hyg 89: 51–57.
-
23.
Zarroug IM et al. 2016. The first confirmed elimination of an onchocerciasis focus in Africa: Abu Hamed, Sudan. Am J Trop Med Hyg 95: 1037–1040.
-
24.
Fitzpatrick C, Fleming FM, Madin-Warburton M, Schneider T, Meheus F, Asiedu K, Solomon AW, Montresor A, Biswas G, 2016. Benchmarking the cost per person of mass treatment for selected neglected tropical diseases: an approach based on literature review and meta-regression with web-based software application. PLoS Negl Trop Dis 10: e0005037.
-
25.
Turner HC, Osei-Atweneboana MY, Walker M, Tettevi EJ, Churcher TS, Asiedu O, Biritwum NK, Basanez MG, 2013. The cost of annual versus biannual community-directed treatment of onchocerciasis with ivermectin: Ghana as a case study. PLoS Negl Trop Dis 7: e2452.
-
26.
Evans D, McFarland D, Adamani W, Eigege A, Miri E, Schulz J, Pede E, Umbugadu C, Ogbu-Pearse P, Richards FO, 2011. Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria. Ann Trop Med Parasitol 105: 537–547.
-
27.
Brady MA, Hooper PJ, Ottesen EA, 2006. Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol 22: 285–291.
-
28.
Downs PW, Bardin LE, McFarland DA, 2014. Modeling the dynamics of incentives in community drug distribution programs. Trends Parasitol 30: 317–319.
-
29.
Fleming FM, Matovu F, Hansen KS, Webster JP, 2016. A mixed methods approach to evaluating community drug distributor performance in the control of neglected tropical diseases. Parasit Vectors 9: 345.
-
30.
Katabarwa M, Habomugisha P, Eyamba A, Agunyo S, Mentou C, 2010. Monitoring ivermectin distributors involved in integrated health care services through community-directed interventions—a comparison of Cameroon and Uganda experiences over a period of three years (2004–2006). Trop Med Int Health 15: 216–223.
-
31.
Chami GF, Kontoleon AA, Bulte E, Fenwick A, Kabatereine NB, Tukahebwa EM, Dunne DW, 2017. Community-directed mass drug administration is undermined by status seeking in friendship networks and inadequate trust in health advice networks. Soc Sci Med 183: 37–47.
-
32.
Wanji S et al. 2015. Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon. Parasit Vectors 8: 667.
-
33.
Cromwell EA, Ngondi J, Gatpan G, Becknell S, Kur L, McFarland D, King JD, Emerson PM, 2009. Estimation of population coverage for antibiotic distribution for trachoma control: a comparison of methods. Int Health 1: 182–189.
-
34.
Worrell C, Mathieu E, 2012. Drug coverage surveys for neglected tropical diseases: 10 years of field experience. Am J Trop Med Hyg 87: 216–222.
-
35.
Cromwell EA, King JD, McPherson S, Jip FN, Patterson AE, Mosher AW, Evans DS, Emerson PM, 2013. Monitoring of mass distribution interventions for trachoma in Plateau State, Nigeria. PLoS Negl Trop Dis 7: e1995.
-
36.
Huhn GD et al. 2006. Vaccination coverage survey versus administrative data in the assessment of mass yellow fever immunization in internally displaced persons—Liberia, 2004. Vaccine 24: 730–737.
-
37.
Zuber PL, Yameogo KR, Yameogo A, Otten MW Jr., 2003. Use of administrative data to estimate mass vaccination campaign coverage, Burkina Faso, 1999. J Infect Dis 187 (Suppl 1): S86–S90.
-
38.
Chami GF, Kontoleon AA, Bulte E, Fenwick A, Kabatereine NB, Tukahebwa EM, Dunne DW, 2016. Profiling nonrecipients of mass drug administration for schistosomiasis and hookworm infections: a comprehensive analysis of praziquantel and albendazole coverage in community-directed treatment in Uganda. Clin Infect Dis 62: 200–207.
-
39.
Okpara EM, Mnaemeka AM, Iyioku UU, Udoh UV, 2015. Distribution and utilisation of ivermectin (Mectizan): a chemotherapeutic approach to the control of onchocerciasis in old Ohaozara Lga, Ebonyi state, eastern Nigeria. J Egypt Soc Parasitol 45: 663–670.
-
40.
Tuhebwe D, Bagonza J, Kiracho EE, Yeka A, Elliott AM, Nuwaha F, 2015. Uptake of mass drug administration programme for schistosomiasis control in Koome Islands, central Uganda. PLoS One 10: e0123673.
-
41.
Rakers LJ, Emukah E, Onyenama J, Amah G, Ukairo N, Enyinnaya U, Miri E, Richards F, 2009. Sustainability of ivermectin distribution programmes. Lancet 374: 785–786.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 5 | 5 | 5 |
| Full Text Views | 1067 | 203 | 1 |
| PDF Downloads | 457 | 53 | 2 |
Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria
The western region of Edo state in southern Nigeria is highly endemic for onchocerciasis. Despite years of mass drug administration (MDA) with ivermectin (IVM), reports suggest persistently high prevalence of onchocerciasis, presumably because of poor coverage. In 2016, twice-per-year treatment with IVM (combined with albendazole for lymphatic filariasis in the first round where needed) began in five local government areas (LGAs) of Edo state. We undertook a multistage cluster survey within 3 months after each round of MDA to assess coverage. First-round coverage was poor: among 4,942 people of all ages interviewed from 145 clusters, coverage was 31.1% (95% confidence intervals [CI]: 24.1–38.0%). Most respondents were not offered medicines. To improve coverage in the second round, three LGAs were randomized to receive MDA through a “modified campaign” approach focused on improved supervision and monitoring. The other two LGAs continued with standard MDA as before. A similar survey was conducted after the second round, interviewing 3,362 people in 87 clusters across the five LGAs. Coverage was not statistically different from the first round (40.0% [95% CI: 31.0–49.0%]) and there was no significant difference between the groups (P = 0.7), although the standard MDA group showed improvement over round 1 (P < 0.01). The additional cost per treatment in the modified MDA was 1.6 times that of standard MDA. Compliance was excellent among those offered treatment. We concluded that poor mobilization, medicine distribution, and program penetration led to low coverage. These must be addressed to improve treatment coverage in Edo state.
Author Notes
Financial support: This publication was made possible thanks to funding from the U.S. Agency for International Development (USAID) and the ENVISION project led by RTI International. The views expressed in this publication do not necessarily reflect the views of the U.S. Agency for International Development or the U.S. Government. Many additional generous foundations, corporations, and individuals have made the Carter Center’s work in Nigeria possible, including major support from Clarke Cares Foundation/Clarke Mosquito Control, GSK, The Mectizan Donation Program, Merck, Sir Emeka Offor Foundation, and The Task Force for Global Health.
Authors’ addresses: Emily Griswold and Frank O. Richards, The Carter Center, Atlanta, GA, E-mails: emily.griswold@cartercenter.org and frank.richards@cartercenter.org. Abel Eigege, Cephas Ityonzughul, Emmanuel Emukah, Emmanuel S. Miri, Solomon Adelamo, Paul Ugbadamu, and Clement Ikogho, The Carter Center, Nigeria, E-mails: abel.eigege@cartercenter.org, cephas.ityonzughul@cartercenter.org, emmanuel.emukah@cartercenter.org, emmanuel.miri@cartercenter.org, solomon.adelamo@cartercenter.org, paul.ugbadamu@cartercenter.org, and clement.ikogho@cartercenter.org. Ifeoma Anagbogu and Yisa A. Saka, Federal Ministry of Health, Nigeria, E-mails: ifechuba@yahoo.co.uk and yisaasaka@yahoo.com. Saliu Kadiri, Edo State Ministry of Health, Nigeria, E-mail: saliu.kadiri@yahoo.com.